The 15 most recent market catalysts affecting $SLS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 75
SELLAS Life Sciences Commences $150 Million Public Offering of Common Stock
SELLAS Life Sciences Group, Inc. has initiated an underwritten public offering to raise $150 million through the sale of its common stock, with an additional option for underwriter…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 95
SELLAS Life Sciences Announces Positive Topline Results from Pivotal Phase 3 REGAL Trial
SELLAS Life Sciences reported highly positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML). The trial met its prima…
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 85
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Corporate Update
SELLAS Life Sciences announced its third-quarter 2026 financial results, showing a healthy cash position of $134.7 million. The primary focus of the filing, however, is the upcomin…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Solaris Resources Receives Final US$50 Million Tranche from Royal Gold Funding Package
Solaris Resources announced the receipt of the final US$50 million tranche from its funding package with Royal Gold, Inc., marking the completion of this financial arrangement. Thi…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 75
SELLAS Life Sciences to Present Phase 2 Data for SLS009 in Relapsed/Refractory AML at ASH 2026
SELLAS Life Sciences announced that it will present Phase 2 data for its drug SLS009 in relapsed/refractory AML at the ASH 2026 meeting. The disclosed results, including an ORR of …
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Institutional Investors Increase Stakes in SELLAS Life Sciences
The filing indicates that major institutional investors like BlackRock, Creative Planning, and Kestra Advisory Services have substantially increased their stakes in SELLAS Life Sci…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 65
SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
SELLAS Life Sciences announced positive preclinical data for its highly selective CDK9 inhibitor, SLS009, in pancreatic cancer models. The data showed SLS009 increased apoptosis si…
Sep 11, 2026
Market Technicals
Neutral
Impact 55
10 Health Care Stocks With Whale Alerts In Today’s Session
The filing details 'whale alerts' in the options market for ten healthcare stocks, indicating large, potentially informed trades. This matters because significant options activity …
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
SELLAS Life Sciences announced the acceptance of three abstracts for poster presentation at the AACR Conference on Pancreatic Cancer. These abstracts detail preclinical activity of…
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 85
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
BMF Capital's short report on SELLAS Life Sciences (SLS) is a significant event for the company and its investors. The report directly challenges the validity of the ongoing Phase …
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
The core event is the FDA approval of Revolution Medicines' Rasonque for metastatic pancreatic adenocarcinoma. This approval is a direct positive catalyst for RVMD, validating a ne…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 75
SL Science Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes
The filing of an FDA Drug Master File (DMF) is a crucial step in the drug development process, streamlining regulatory review for future products utilizing the GDT Cell-Derived Exo…
Aug 21, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
This filing is a 'whale alert' indicating large-scale options trading activity in several health care stocks. Such activity, particularly 'sweeps' (orders split across multiple exc…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 92
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
SELLAS Life Sciences Group (SLS) announced Q2 earnings per share (EPS) of $(0.05), which significantly missed the consensus analyst estimate of $(0.04). This 25% miss, coupled with…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.